Keros Therapeutics, Inc.

For the period ended Sep 30, 2025. Filed Nov 5, 2025.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Sep 30, 2025 · Filed Nov 5, 2025

KROS$9.33+1.7%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Condensed Consolidated Statements of Operations

	THREE MONTHS ENDED SEPTEMBER 30,		NINE MONTHS ENDED SEPTEMBER 30,
	2025	2024	2025	2024
REVENUE:
Service and other revenue	$4,262	$388	$38,321	$508
License revenue	10,000	—	205,355	—
Total revenue	14,262	388	243,676	508
OPERATING EXPENSES:
Research and development	(19,519)	(49,225)	(111,731)	(127,998)
General and administrative	(10,127)	(9,820)	(35,106)	(30,089)
Total operating expenses	(29,646)	(59,045)	(146,837)	(158,087)
INCOME (LOSS) FROM OPERATIONS	(15,384)	(58,657)	96,839	(157,579)
OTHER INCOME (EXPENSE), NET
Dividend income	6,933	5,793	20,845	16,977
Other expense, net	(253)	(92)	(812)	(725)
Total other income, net	6,680	5,701	20,033	16,252
Income (loss) before income taxes	(8,704)	(52,956)	116,872	(141,327)
Income tax (provision) benefit	1,424	—	(6,397)	—
Net income (loss)	$(7,280)	$(52,956)	$110,475	$(141,327)
Net income (loss) attributable to common stockholders — basic and diluted (Note 8)	$(7,280)	$(52,956)	$110,475	$(141,327)
Weighted-average shares of common stock outstanding — basic	40,623,364	37,590,727	40,598,777	36,463,906
Weighted-average shares of common stock outstanding — diluted	40,623,364	37,590,727	41,202,371	36,463,906
Net income (loss) per share of common stock — basic	$(0.18)	$(1.41)	$2.72	$(3.88)
Net income (loss) per share of common stock — diluted	$(0.18)	$(1.41)	$2.68	$(3.88)

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.